If you have been reading about 白蛋白结合 and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2025-12-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
The GIP receptor is expressed in pancreatic islets, adipose tissue, and the central nervous system, while GLP-1 receptors are found in pancreatic islets, the gastrointestinal tract, and the brain. Activation of both receptors can enhance glucose-dependent insulin secretion and reduce glucagon release. The relative contribution of each receptor to the overall pharmacological effect remains an area of ongoing investigation. Preclinical studies suggest that GIP receptor agonism may modulate appetite and energy balance, but the precise mechanisms in humans are not fully established.
In clinical research, tirzepatide has been studied in randomized controlled trials for glycemic control and body weight reduction. These trials typically measure changes in hemoglobin A1c and body weight over periods of several months. The drug is administered by subcutaneous injection, and its pharmacokinetic profile supports once-weekly dosing. Post-marketing surveillance continues to evaluate long-term outcomes and rare adverse events.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C225H348N48O68 | Peptide backbone with a fatty diacid chain |
| Molecular weight | About 4813 Da | Calculated from the formula |
| Receptor targets | GIP and GLP-1 receptors | Dual agonist activity at both sites |
| Route of administration | Subcutaneous injection | No approved oral form at present |
| Elimination half-life | About 5 days | Supports extended intervals between administrations |
Tirzepatide is a synthetic peptide built from thirty-nine amino acids. Its sequence is derived from native glucose-dependent insulinotropic polypeptide, or GIP, with several non-natural residues and a fatty diacid side chain attached through a linker. The molecule behaves as a dual agonist at two incretin receptors, GIP and GLP-1, instead of targeting a single receptor. This dual engagement separates it from earlier single-receptor incretin compounds and underpins most of its reported pharmacological activity.
At the receptor level, the compound binds both GIP and GLP-1 receptors and triggers downstream signalling that raises cyclic AMP in target cells. GLP-1 receptor activation is associated with glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. GIP receptor activation contributes effects that are less completely characterised, and how much each receptor adds to the overall clinical response is still an open question. The two pathways appear to interact in a complementary rather than a purely additive way.
Receptor activation by tirzepatide raises intracellular cyclic AMP through Gs-coupled signalling at both targets. At the GLP-1 receptor the downstream effect includes glucose-dependent insulin release, suppressed glucagon secretion, delayed gastric emptying, and reduced appetite signalling in the hypothalamus. GIP receptor engagement adds insulinotropic activity and appears to influence lipid handling in adipose tissue. Because both receptors are stimulated at the same time, the pharmacological profile differs from that of selective GLP-1 receptor agonists, and the relative contribution of each arm remains an area of active investigation.
Clinical development proceeded through large phase 3 programmes in type 2 diabetes and in obesity or overweight with at least one weight-related comorbidity. Regulatory approvals followed in several jurisdictions for both indications. Weekly subcutaneous dosing reflects an elimination half-life of roughly five days. Open questions include the durability of metabolic effects after treatment stops, long-term cardiovascular and hepatic outcomes beyond completed trials, and whether the dual mechanism confers benefits independent of total receptor occupancy. Published literature continues to expand on these points. Substantial uncertainty remains about interindividual variability in response.
Tirzepatide is a synthetic linear peptide of 39 amino acids that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. Its sequence derives from native GIP but incorporates non-natural residues and a C20 fatty diacid moiety linked to a lysine side chain. The lipophilic chain promotes albumin binding, which slows renal clearance and extends circulation time. The unmodified peptide has a molecular formula of C225H348N48O68 and a molecular mass near 4,813 daltons.
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
该化合物的名称与结构由国际非专利名称体系统一维持，不同文献中出现的同义写法主要在拼写顺序或盐形式描述上不同。研究者通常通过受体结合实验、细胞内环磷酸腺苷积累测定以及动物模型来确认其双激动活性。相当一部分分子层面的细节——例如两条受体通路之间的信号交叉作用——尚处于开放问题状态。
当前公开资料把 tirzepatide 归为肠促胰素类受体双重激动剂。它并非激素天然变体，而是经过序列改造的工程化肽。其分子量、等电点与疏水性等基础参数已在药典和化学数据库中收录，可作为分析检测和质量研究的参照。
Tirzepatide 是一种由 39 个氨基酸组成的合成肽，分子结构上以 GIP 序列为骨架并引入脂肪酸侧链修饰，使其能够同时与葡萄糖依赖性促胰岛素多肽（GIP）受体和胰高血糖素样肽-1（GLP-1）受体结合。这种双重激动特性使它在同类肽类药物中区别于选择性 GLP-1 受体激动剂。该分子最早由一家制药公司在 2010 年代报道，随后进入糖尿病与体重管理领域的临床研究。
In California, Adorno made the acquaintance of Charlie Chaplin and became friends with Fritz Lang and Hanns Eisler, with whom he completed a study of film music in 1944. In this study, the authors pushed for the greater usage of avant-garde music in film, urging that music be used to supplement, not simply accompany, films' visual aspects. Adorno also assisted Thomas Mann with his novel Doktor Faustus after the latter asked for his help. "Would you be willing," Mann wrote, "to think through with me how the work—I mean, Leverkühn's work—might look; how you would do it if you were in league with the Devil?" At the end of October 1949, Adorno left America for Europe just as The Authoritarian Personality was being published. Before his return, Adorno had reached an agreement with a Tübingen publisher to print an expanded version of Philosophy of New Music and completed two compositions: Four Songs for Voice and Piano by Stefan George, op. 7, and Three Choruses for Female Voices from the Poems of Theodor Däubler, op. 8.
== Signs and symptoms == Hallmark symptoms of ciguatera in humans include gastrointestinal, cardiovascular, and neurological effects. Gastrointestinal symptoms include nausea, vomiting, and diarrhea, usually followed by neurological symptoms such as headaches, muscle aches, numbness of the extremities, mouth and lips, reversal of hot and cold sensation, ataxia, vertigo, and hallucinations. Severe cases of ciguatera can also result in cold allodynia, which is a burning sensation on contact with cold. Neurological symptoms can persist and ciguatera poisoning is occasionally misdiagnosed as multiple sclerosis. Cardiovascular symptoms include bradycardia, tachycardia, hypotension, hypertension, orthostatic tachycardia, exercise intolerance, and abnormal electrocardiograms. Death from the condition can occur, but is very rare. Dyspareunia and other ciguatera symptoms have developed in otherwise healthy males and females following sexual intercourse with partners suffering ciguatera poisoning, signifying that the toxin may be sexually transmitted. Diarrhea and facial rashes have been reported in breastfed infants of poisoned mothers, suggesting that the polyether toxins partition into breast milk. The symptoms can last from weeks to months, and in extreme cases as long as 20 years, often leading to long-term disability. Most people do recover slowly over time, but genetically susceptible individuals are not able to remove the toxin and will remain sick indefinitely without medical treatment
== Mosaic Diagnostics, formerly Great Plains Laboratory == William Shaw's laboratory is known for performing nonstandard tests which have been used by alternative medicine practitioners to support discredited diagnoses. Great Plains Laboratory's urine mycotoxin test is not validated nor recommended for diagnosing any condition. In May 2020, early in the COVID-19 pandemic, Great Plains marketed unproven antibody tests.
Pakistan cricket spot-fixing scandal – in 2010, three Pakistan players—team captain Salman Butt, Mohammad Asif and Mohammad Amir—were accused of involvement in a spot-fixing scheme in which they allegedly accepted large sums of money to influence specific events within a match, as opposed to an actual match result. After an investigation, the ICC banned all three from the sport for periods from 5 to 10 years. Later, Butt and Asif were tried in a London court and found guilty of charges related to the scheme, whilst Amir pleaded guilty to similar charges in the same court. All received prison sentences ranging from 6 to 30 months. 2013 Indian Premier League spot-fixing and betting case 2018 Australian ball-tampering scandal - In 2018, When Australia toured South Africa, Australia's Cameron Bancroft was seen on camera rubbing the ball with a small yellow object then hid the object in his underwear. The umpires then ruled he was ball tampering. It was then found that Australian captain Steve Smith and vice captain David Warner were also found to have been involved in the incident. Smith and Warner were then banned for 12 months from international and domestic cricket while Bancroft was banned for 9 months. Smith was also temporarily banned from captaining Australia while Warner received a life ban from captaining. 2018 Sri Lankan cricket pitch fixing and betting scandal
Sources: en.wikipedia.org
Modern mass spectra are usually analyzed using software: computers can search through libraries of known mass spectra peaks much faster than humans could. For peaks not found in the library, computers can simulate ionization and fragmentation processes (as well as isotope combinations) to generate hypothetical peaks to match against. Many databases of experimental peaks as well as pre-calculated hypothetical peaks are available; these can be combined in looking for a suitable interpretation of a peak.
=== Pharmacodynamics === The actions and effects of nutmeg and its constituents in in-vitro systems and animals have been described and reviewed. Nutmeg constituents like myristicin and elemicin have been reported to interact with serotonin receptors. In a subsequent study however, nutmeg extracts showed no affinity for any of the serotonin receptors nor for various other receptors including the muscarinic acetylcholine receptors among others (all <50% binding inhibition at 10,000 nM). Myristicin has been found to act as a weak monoamine oxidase inhibitor (MAOI). Neither myristicin nor elemicin produce the head-twitch response, a behavioral proxy of psychedelic effects, in rodents. However, in another study, elemicin did produce the head-twitch response. On the other hand, myristicin failed to produce electroencephalogram (EEG) activation and behavioral effects similar to those of psychedelic amphetamines such as MMDA in animals. Another study also reported that myristicin did not produce amphetamine-like behavioral effects in rodents. Nutmeg extracts were compared to Δ9-tetrahydrocannabinol (Δ9-THC), amphetamine, and morphine in rodents and one extract was found to have various activities including some cannabimimetic-like effects. No affinity for the cannabinoid CB1 and CB2 receptors was found (<50% binding inhibition at 10,000 nM).
As the popularity of TikTok grows, more and more individuals join the platform. Hence, current political ideologies are being spread on the platform. TikTok has turned into a political landscape, where young individuals are consuming far-right related content on a daily basis. TikTok has allowed for far-right supporters to have a platform where radical views are naturalized. Statistics have shown that roughly 14% of adults regularly get their election and political news through the platform. TikTok has addressed multiple times that hateful content, related to far-right ideologies, is being banned and removed from their platform. However, most hateful content (related to religion, identity, race) have gone unnoticed by the system until December 2019. Although user protection has improved, hateful videos still go undetected by the platform. In light of recent political tensions on the app, the usage of violent commentary has been more prevalent on the app, more-so from the left wing commenters. An article that evaluated the level of politically violent comments on the app concluded that leftist content also alienates what is perceived as the "enemy" at larger rates and even are more likely to make violent references as well. Additionally, those comments were statistically less inclined to express religious beliefs openly. On the flip side, right wing content relies more heavily on toxicity to spread a message and gain more views. Additionally, since TikTok functions on an algorithmic system, individuals can get more exposure to hateful content without intending to do so.
Sources: en.wikipedia.org
It is a synthetic 39-amino-acid peptide that acts on two incretin receptors, the GIP receptor and the GLP-1 receptor. It is given by subcutaneous injection and has a circulating half-life of roughly five days. It is not a small molecule and is not absorbed usefully from the gut in conventional oral form.
Selective agents act on one receptor, while tirzepatide engages both GIP and GLP-1 receptors. The added GIP activity may contribute effects on insulin sensitivity and on fat metabolism. Whether the dual action produces meaningful clinical advantages beyond differences in potency is still being examined.
The downstream consequences of GIP receptor activation are not fully characterised in humans. It is also unclear how much each receptor contributes to appetite reduction and to shifts in body composition. Published work describes associations and proposed pathways rather than settled causal chains.
It activates both GIP and GLP-1 receptors. This dual action differentiates it from selective GLP-1 agonists.